Sector: Healthcare · Industry: Biotechnology · Exchange: Euronext Paris
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Headquarters: Paris, FR · Employees: 98 · Website: https://www.nanobiotix.com
Nanometrics Incorporated (NANO) is a publicly traded company in the Healthcare sector (Biotechnology), listed on Euronext Paris. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.
Competitors of Nanometrics Incorporated (NANO) tracked by Macroplane include NVIDIA CORP (NVDA), TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM), Broadcom Inc. (AVGO), Taiwan Semiconductor Manufacturing Company Limited (TSMC) (2330), Samsung Electronics Co., Ltd. (005930.KS), SK Hynix Inc. (000660.KS), ADVANCED MICRO DEVICES INC (AMD), MICRON TECHNOLOGY INC (MU), and 4 more.
Search companies · Macro trends · Industries · Product categories · Baskets